GROWTH HORMONE / PEPTIDE CARD

Tesamorelin

A growth hormone-releasing hormone analog with an FDA-approved use for a specific HIV-associated lipodystrophy population.

PEPTIDE CARDTesamorelin

Reviewed
August 7, 2026

Human evidence

5/5 · Approved indication

U.S. FDAIndication-specific approval

2026 WADAProhibited

Inspect 3 sources

On this page

WHAT THE EVIDENCE SAYS

Tesamorelin evidence summary.

Tesamorelin has the strongest human evidence in a narrow, labeled population. Evidence from that population should not be generalized to routine weight management.

Entity type
Peptide analogSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

Approval is product-, indication-, and population-specific. It does not validate every compounded formulation or off-label claim.

01 / CLASSIFICATION

What is Tesamorelin?

Entity typePeptide analog

Research categoryGrowth Hormone

Known namesTesamorelin

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Growth-hormone-axis peptides Goal: Growth Hormone Axis Goal: Visceral Fat Research

02 / EVIDENCE

Tesamorelin human and preclinical evidence.

HUMAN

5/5 · Approved indication

Multiple randomized trials support one specific FDA-approved indication in adults with HIV and lipodystrophy.

PRECLINICAL

3/5 · Mechanism supported

Growth-hormone-releasing activity is well characterized, but approved-use evidence is human and indication-specific.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

Tesamorelin FDA and sport status.

U.S. FDAFDA approved only to reduce excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight-loss management.

2026 WADAProhibited at all times under the 2026 WADA List (S2).

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is Tesamorelin being studied for?

01HIV lipodystrophy

02Visceral adipose tissue

03Liver fat

04Growth hormone axis

05 / COMPARISONS

Compare Tesamorelin.

Tesamorelin vs SermorelinCurrent approval and evidence context for two GHRH analogs.Tesamorelin vs IpamorelinAn approved GHRH analog compared with an unapproved ghrelin-receptor agonist.CJC-1295 vs TesamorelinAn unapproved endocrine research peptide compared with an indication-specific approved medicine.AOD-9604 vs TesamorelinA growth-hormone fragment with an unsuccessful obesity program compared with a narrow approved GHRH analog.Tesamorelin vs SemaglutideA narrow HIV-lipodystrophy medicine compared with product-specific metabolic indications.Tesamorelin vs TirzepatideIndication-specific HIV-lipodystrophy evidence compared with dual-incretin metabolic evidence.

06 / LATEST & DEFINING SOURCES

Tesamorelin primary and official sources.

FDA / 2025EGRIFTA WR prescribing information

U.S. FDA

Human trial / 2010Pooled analysis of two Phase 3 tesamorelin trials

PubMed

WADA / 20262026 Prohibited List

World Anti-Doping Agency

07 / QUESTIONS

Questions about Tesamorelin.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for Tesamorelin?

Tesamorelin has the strongest human evidence in a narrow, labeled population. Evidence from that population should not be generalized to routine weight management.

ResearchWhat is Tesamorelin being studied for?

Current source-backed research areas include HIV lipodystrophy, Visceral adipose tissue, Liver fat, Growth hormone axis. These areas describe investigation, not established personal benefit.

FDA statusIs Tesamorelin FDA approved?

Current U.S. status for Tesamorelin: FDA approved only to reduce excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight-loss management.

Sport statusIs Tesamorelin prohibited in sport?

Current sport-status snapshot for Tesamorelin: Prohibited at all times under the 2026 WADA List (S2).

Evidence limitsWhat are the main evidence limits for Tesamorelin?

Approval is product-, indication-, and population-specific. It does not validate every compounded formulation or off-label claim.

Decision questionWhat is currently being studied for visceral fat?

The evidence depends on the population and the question. An approved indication, obesity treatment, and investigational research should not be collapsed into one list.

Decision questionHow do tesamorelin, sermorelin, CJC-1295, and ipamorelin differ?

They all interact with the growth-hormone axis, but through different receptors, with very different clinical and regulatory maturity.